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BACKGROUND
The subcutaneous implantable cardioverter–defibrillator (ICD) was designed to 
avoid complications related to the transvenous ICD lead by using an entirely extra-
thoracic placement. Evidence comparing these systems has been based primarily 
on observational studies.
METHODS
We conducted a noninferiority trial in which patients with an indication for an ICD 
but no indication for pacing were assigned to receive a subcutaneous ICD or trans-
venous ICD. The primary end point was the composite of device-related complica-
tions and inappropriate shocks; the noninferiority margin for the upper boundary 
of the 95% confidence interval for the hazard ratio (subcutaneous ICD vs. trans-
venous ICD) was 1.45. A superiority analysis was prespecified if noninferiority was 
established. Secondary end points included death and appropriate shocks.
RESULTS
A total of 849 patients (426 in the subcutaneous ICD group and 423 in the trans-
venous ICD group) were included in the analyses. At a median follow-up of 49.1 
months, a primary end-point event occurred in 68 patients in the subcutaneous 
ICD group and in 68 patients in the transvenous ICD group (48-month Kaplan–
Meier estimated cumulative incidence, 15.1% and 15.7%, respectively; hazard ratio, 
0.99; 95% confidence interval [CI], 0.71 to 1.39; P = 0.01 for noninferiority; P = 0.95 
for superiority). Device-related complications occurred in 31 patients in the subcu-
taneous ICD group and in 44 in the transvenous ICD group (hazard ratio, 0.69; 
95% CI, 0.44 to 1.09); inappropriate shocks occurred in 41 and 29 patients, respec-
tively (hazard ratio, 1.43; 95% CI, 0.89 to 2.30). Death occurred in 83 patients in 
the subcutaneous ICD group and in 68 in the transvenous ICD group (hazard ratio, 
1.23; 95% CI, 0.89 to 1.70); appropriate shocks occurred in 83 and 57 patients, 
respectively (hazard ratio, 1.52; 95% CI, 1.08 to 2.12).
CONCLUSIONS
In patients with an indication for an ICD but no indication for pacing, the sub-
cutaneous ICD was noninferior to the transvenous ICD with respect to device-
related complications and inappropriate shocks. (Funded by Boston Scientific; 
PRAETORIAN ClinicalTrials.gov number, NCT01296022.)
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Implantable cardioverter–defibrilla-tors (ICDs) have been proven to be effica-cious in the prevention of sudden cardiac 
death.1-3 Transvenous lead placement for cardiac 
sensing and defibrillation has been the standard 
for ICD design for several decades. However, 
important limitations of the technique include 
complications related to lead insertion, such as 
pneumothorax and cardiac perforation, and long-
term complications, such as lead endocarditis 
and lead dysfunction.4 To avoid such complica-
tions, an entirely subcutaneous ICD was intro-
duced as an alternative.5 The extrathoracic place-
ment of the subcutaneous ICD circumvents the 
need to enter the heart and vasculature but 
makes it impossible for the device to deliver pac-
ing therapy.
Class IIa recommendations for the subcuta-
neous ICD in U.S. and European guidelines for 
patients in whom pacing therapy for bradycardia, 
cardiac resynchronization, or antitachycardia 
pacing is not indicated are based on experience 
from observational studies.6-9 The Prospective 
Randomized Comparison of Subcutaneous and 
Transvenous Implantable Cardioverter Defibril-
lator Therapy (PRAETORIAN) trial evaluated 
whether the subcutaneous ICD would be non-
inferior to the transvenous ICD with regard to 
short-term and long-term device-related compli-
cations and inappropriate shocks.
Me thods
Trial Design and Oversight
We conducted this investigator-initiated, inter-
national, randomized, noninferiority trial in the 
United States and Europe. The principal coordi-
nating investigators were responsible for the 
design of the trial, which has been published 
previously.10 The Academic Medical Center Am-
sterdam was responsible for site contracting, 
data collection, monitoring, and management. 
Trial design and execution were overseen by a 
steering committee, and the conduct of the trial 
and the safety of the patients were overseen by 
an independent data and safety monitoring 
board. The protocol, which is available with the 
full text of this article at NEJM.org, was ap-
proved by the institutional review board at all 
participating centers.
This trial was funded by Boston Scientific, 
which had no role in the design of the trial, 
analysis of the data, or the drafting and submis-
sion of the manuscript. The principal investiga-
tors analyzed the data in accordance with the 
statistical analysis plan and prepared the manu-
script. The authors vouch for the accuracy and 
completeness of the data and for the fidelity of 
the trial to the protocol.
Trial Population
Patients were eligible for entry into this trial if 
they were 18 years of age or older and had a 
class I or IIa indication for ICD therapy for pri-
mary or secondary prevention, according to the 
guidelines from the American College of Cardi-
ology–American Heart Association Task Force 
on Clinical Practice Guidelines and the Heart 
Rhythm Society or those from the European 
Society of Cardiology.6,8 Key exclusion criteria 
were previous ICD implantation, unsuitability for 
subcutaneous ICD therapy according to QRS-T–
wave sensing analysis (see the Supplementary 
Appendix, available at NEJM.org), and indica-
tions for either bradycardia pacing or biventricu-
lar pacing. We also excluded patients with known 
ventricular tachycardia at a rate below 170 beats 
per minute or with refractory recurrent mono-
morphic ventricular tachycardia that could not 
be managed with medication or ablation therapy 
because, for such patients, antitachycardia pac-
ing was considered to be an especially important 
therapeutic option. Detailed inclusion and exclu-
sion criteria are provided in the Supplementary 
Appendix. All the patients provided written in-
formed consent.
Randomization and Procedures
Eligible patients were randomly assigned in a 1:1 
ratio to receive either a subcutaneous ICD or 
transvenous ICD, with stratification according 
to center. Block sizes ranging from two to eight 
were used to conceal treatment assignments. 
All subcutaneous ICDs were manufactured by 
Cameron Health–Boston Scientific. The choice 
of transvenous ICD manufacturer was at the 
discretion of the physician performing the im-
plantation. All transvenous ICDs were single-
chamber devices unless a dual-chamber device 
was deemed to be necessary for the discrimina-
tion of arrhythmia. The procedures regarding 
implantation, defibrillation testing, and hospital 
discharge followed local clinical practice. All 
the patients were seen at a follow-up visit with-
The New England Journal of Medicine 
Downloaded from nejm.org by ${individualUser.givenNames} ${individualUser.surname} on August 14, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 383;6 nejm.org August 6, 2020528
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
in 4 months after implantation. Thereafter, ICDs 
were interrogated at least twice per year, and 
patients had at least one annual visit to the out-
patient clinic.
ICD Programming
Programming of the parameters for the detec-
tion of ventricular tachycardia or ventricular fi-
brillation and for therapeutic variables was stan-
dardized and based on the best available evidence 
at the time of protocol development.11 Program-
ming strategies were comparable between the 
two treatment groups. The cutoff for the fast 
ventricular tachycardia zone was set as close to 
182 beats per minute as possible, given differ-
ences in manufacturer programming options, 
with one burst of antitachycardia pacing for the 
transvenous ICD. The cutoff for the ventricular 
fibrillation zone was 250 beats per minute. De-
viation from the recommended device program-
ming was allowed in order to fit the specific 
characteristics of the patient. Details are pro-
vided in the Supplementary Methods section in 
the Supplementary Appendix.
End Points
The composite primary end point of the trial 
consisted of device-related complications and 
inappropriate shocks. Complications included 
device infection that led to the extraction of the 
lead or generator; pocket hematoma that led to 
drainage, blood transfusion, or prolongation of 
hospitalization; device-related thrombotic events; 
pneumothorax or hemothorax that led to inter-
vention or prolongation of hospitalization; cardi-
ac perforation or tamponade; lead repositioning 
or replacement; and other complications related 
to the lead or generator that led to medical or 
surgical intervention. An ICD shock was classi-
fied as inappropriate when it was delivered for 
any rhythm other than ventricular fibrillation or 
ventricular tachycardia. Secondary end points 
included the individual components of the pri-
mary end point, death from any cause, appropri-
ate ICD therapy (including antitachycardia pacing), 
major adverse cardiac events, hospitalization for 
heart failure, and crossover between the assigned 
devices.
A clinical-events committee consisting of three 
electrophysiologists who were not otherwise in-
volved in the trial adjudicated all clinical and 
arrhythmic events. Shock therapy and other ar-
rhythmic events that were derived from regular 
device interrogation were classified as being ei-
ther appropriate or inappropriate according to 
the rhythm that initiated the therapy. Hence, 
shocks without electrograms were not adjudi-
cated. A complete overview of trial end points 
and definitions is provided in the Supplementary 
Appendix.
Statistical Analysis
The trial was designed to test the hypothesis of 
noninferiority of the subcutaneous ICD as com-
pared with the transvenous ICD with respect to 
the time from device implantation to the first 
occurrence of a primary end-point event. The 
noninferiority margin for the upper boundary of 
the 95% confidence interval for the hazard ratio 
was set at 1.45. The estimation of cumulative 
incidence and sample-size justification have been 
reported previously.10 We estimated that the oc-
currence of a primary end-point event in the 
transvenous ICD group would be 17.2% at 48 
months.1,11 Assuming that 5% of patients would 
discontinue the trial, we calculated that the en-
rollment of 425 patients in each group would 
provide the trial with 85% power to show non-
inferiority of the subcutaneous ICD at a one-sided 
alpha level of 0.025. A superiority analysis was 
prespecified if noninferiority was established.
Analyses for all the end points were per-
formed in the modified intention-to-treat popu-
lation, which included patients according to the 
group to which they had been randomly as-
signed, regardless of the device they received. 
Patients who did not receive either device after 
randomization or who underwent randomiza-
tion in error were excluded from the analyses. 
A sensitivity analysis was performed in the as-
treated population, which included patients ac-
cording to the treatment that they first received. 
Additional sensitivity analyses included, among 
others, a competing-risks analysis to account for 
death and incomplete follow-up, an analysis to 
account for missing electrographic data from 
the device, and a multiple imputation analysis by 
fully conditional specification.12
For the time-to-event analyses, cumulative 
incidence curves were constructed with the use 
of the Kaplan–Meier method, and hazard ratios 
and 95% confidence intervals were calculated by 
Cox proportional-hazards models. For these analy-
ses, missing data were presumed to be missing 
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at random, and data were censored for patients 
with incomplete follow-up on the last known 
event-free day. The confidence intervals were not 
adjusted for multiplicity and therefore should 
not be used to infer definitive treatment effects. 
Prespecified subgroups that were defined ac-
cording to age, sex, and body-mass index were 
analyzed for the occurrence of a primary end-
point event. Additional information regarding 
the statistical analyses is provided in the Supple-
mentary Appendix. Statistical analyses were per-




From March 2011 through January 2017, a total 
of 876 patients were enrolled at 39 centers in 
Europe and the United States (Fig. 1 and Table S1 
Figure 1. Randomization, Implantation, and Follow-up of the Patients.
Screening details and the reasons for exclusion are presented in Figure S1 and Table S2, respectively. A total of 16 
patients in the group that was assigned to receive the subcutaneous implantable cardioverter–defibrillator (ICD) 
and 11 patients in the group that was assigned to receive the transvenous ICD were excluded from the modified 
 intention-to-treat analysis because they either did not undergo ICD implantation or had undergone randomization 
in error. A total of 4 patients in the subcutaneous ICD group and 6 patients in the transvenous ICD group never 
 underwent any attempt to implant the assigned device but instead received the alternate device. A total of 70 pa-
tients in the subcutaneous ICD group and 56 patients in the transvenous ICD group died before having a composite 
primary end-point event (device-related complication or inappropriate shock).
876 Patients underwent randomization
442 Were assigned to receive
subcutaneous ICD
434 Were assigned to receive
transvenous ICD
16 Were excluded
8 Did not undergo ICD implan-
tation
5 Withdrew informed consent
2 Died before implantation
1 Received diagnosis of cancer
8 Did not meet eligibility criteria
11 Were excluded
10 Did not undergo ICD implan-
tation
8 Withdrew informed consent
2 Died before implantation
1 Did not meet eligibility criteria
426 Were included in the modified
intention-to-treat analysis
422 Received subcutaneous ICD
4 Received transvenous ICD
2 Received device owing 
to physician’s preference
1 Received device owing 
to patient’s preference 
1 Had atrioventricular block
after randomization
423 Were included in the modified
intention-to-treat analysis
417 Received transvenous ICD
6 Received subcutaneous ICD
owing to patient’s preference
339 Had complete follow-up for 
primary end point
87 Had incomplete follow-up
70 Died
2 Withdrew consent for further
follow-up
15 Were lost to follow-up
 
14 Switched to transvenous ICD
during follow-up
346 Had complete follow-up for
primary end point
77 Had incomplete follow-up
56 Died
9 Withdrew consent for further
follow-up
12 Were lost to follow-up
5 Switched to subcutaneous ICD
during follow-up
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in the Supplementary Appendix). Information 
about patients who underwent screening and 
reasons for exclusion are provided in Figure S1 
and Table S2. Of the 876 patients enrolled, 27 
were excluded from the primary analysis; 18 did 
not undergo ICD implantation and 9 had under-
gone randomization in error. A total of 849 pa-
tients were included in the primary analysis; of 
these patients, 426 were randomly assigned to 
the subcutaneous ICD group and 423 to the 
transvenous ICD group (Fig. 1). The clinical 
characteristics of the patients at baseline were 
similar in the two groups (Table 1). The median 
age of the patients was 63 years (interquartile 






Median age (IQR) ― yr 63 (54–69) 64 (56–70)
Female sex ― no. (%)  89 (20.9)  78 (18.4)
Diagnosis ― no. (%)
Ischemic cardiomyopathy 289 (67.8) 298 (70.4)
Nonischemic cardiomyopathy  99 (23.2)  98 (23.2)
Genetic arrhythmia syndrome 20 (4.7) 18 (4.3)
Hypertrophic cardiomyopathy 15 (3.5)  7 (1.7)
Idiopathic ventricular fibrillation 11 (2.6)  5 (1.2)
Congenital heart disease  3 (0.7)  3 (0.7)
Other†  4 (0.9)  1 (0.2)
Secondary prevention ― no. (%)  80 (18.8)  84 (19.9)
Median ejection fraction (IQR) ― % 30 (25–35) 30 (25–35)
Mean QRS duration ― msec 105±19 105±20
NYHA class ― no./total no. (%)
I 144/423 (34.0) 134/421 (31.8)
II 205/423 (48.5) 223/421 (53.0)
III or IV  74/423 (17.5)  64/421 (15.2)
Median body-mass index (IQR)‡ 27.0 (24.5–30.5) 27.9 (25.2–31.7)
Hypertension or use of antihypertensive drugs ― no./total no. (%) 227/424 (53.5) 240/419 (57.3)
Hypercholesterolemia or use of lipid-lowering drugs ― no./total no. (%) 161/419 (38.4) 175/418 (41.9)
Current or recent smoking ― no./total no. (%) 119/406 (29.3) 139/401 (34.7)
Diabetes mellitus ― no./total no. (%) 112/426 (26.3) 126/421 (29.9)
Previous CABG ― no./total no. (%)  86/425 (20.2)  85/421 (20.2)
History of atrial fibrillation ― no./total no. (%) 115/426 (27.0)  93/420 (22.1)
History of nonsustained ventricular tachycardia ― no./total no. (%)  46/423 (10.9)  44/417 (10.6)
History of syncope ― no./total no. (%) 23/420 (5.5) 33/418 (7.9)
Site location ― no. (%)
Europe 394 (92.5) 395 (93.4)
United States 32 (7.5) 28 (6.6)
Median time from randomization to device implantation (IQR) — days 7.5 (1.0–29.0) 6.0 (1.0–26.5)
*  Plus–minus values are means ±SD. CABG denotes coronary-artery bypass grafting, ICD implantable cardioverter–defi-
brillator, IQR interquartile range, and NYHA New York Heart Association.
†  The patients in this category had ventricular fibrillation due to coronary spasm (one patient in the subcutaneous ICD 
group and one in the transvenous ICD group), coronary dissection (one in the subcutaneous ICD group), ischemic stroke 
(one in the subcutaneous ICD group), and myocarditis (one in the subcutaneous ICD group).
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
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range, 55 to 70); 19.7% of the patients were 
women, and 69.1% had ischemic cardiomyopa-
thy. The median left ventricular ejection fraction 
was 30%.
Details of the initial implantation procedure 
are provided in Table S3. Of the patients in the 
transvenous ICD group, 48 (11.3%) received a 
dual-chamber device at initial implantation. A 
total of 10 patients crossed over to the other 
device without any attempt to implant the as-
signed device. Five additional patients crossed 
over shortly after initial implantation, and 14 
patients crossed over during follow-up. Details 
of all the crossovers are provided in Table S4. 
Details of adherence to the device programming 
protocol are provided in Table S5.
Follow-up and Primary End Point
Follow-up of the trial was completed on Decem-
ber 1, 2019. A total of 339 patients in the sub-
cutaneous ICD group and 346 patients in the 
transvenous ICD group had complete follow-up 
(Fig. 1). The median duration of follow-up was 
49.1 months (48.0 months in the subcutaneous 
ICD group and 50.6 months in the transvenous 
ICD group). The primary end point occurred in 
68 patients in the subcutaneous ICD group and 
in 68 patients in the transvenous ICD group 
(48-month Kaplan–Meier estimated cumulative 
incidence, 15.1% and 15.7%, respectively). The 
hazard ratio for the primary end point was 0.99 
(95% confidence interval [CI], 0.71 to 1.39; non-
inferiority margin, 1.45; P = 0.01 for noninferior-
ity; P = 0.95 for superiority) (Fig. 2A and Table 2).
Device-related complications occurred in 31 
patients in the subcutaneous ICD group and in 
44 patients in the transvenous ICD group (cumu-
lative incidence, 5.9% and 9.8%, respectively; 
hazard ratio, 0.69; 95% CI, 0.44 to 1.09) (Fig. 2B). 
The incidence of complications within the first 
30 days was 3.8% in the subcutaneous ICD group 
and 4.7% in the transvenous ICD group. The 
incidence of complications related to the ICD 
lead was lower in the subcutaneous ICD group 
than in the transvenous ICD group (1.4% vs. 
6.6%) (Fig. S2).
Inappropriate shocks occurred in 41 patients 
in the subcutaneous ICD group and in 29 pa-
tients in the transvenous ICD group (cumulative 
incidence, 9.7% and 7.3%, respectively; hazard 
ratio, 1.43; 95% CI, 0.89 to 2.30) (Fig. 2C). The 
first occurrences of inappropriate shocks in the 
subcutaneous ICD group were most frequently 
caused by cardiac oversensing (in 58.5% of the 
patients with an inappropriate shock), whereas 
inappropriate shocks in the transvenous ICD 
group were more commonly triggered by supra-
ventricular arrhythmia (in 93.1%) (Table 2). De-
viations from the programming protocol at the 
time of first inappropriate shocks are described 
in the Supplementary Results section in the 
Supplementary Appendix; the findings indicated 
that two episodes of inappropriate shocks in the 
transvenous ICD group may have been prevented 
if the prespecified programming had been used.
The findings of the primary analysis were 
consistent in the as-treated population (Fig. S3). 
There were no between-group differences in the 
occurrence of the primary end point across pre-
specified subgroups (Fig. S4). Results of the com-
peting-risks analyses, multivariable analyses, and 
sensitivity analyses that account for missing data 
are provided in Tables S6 through S11.
Secondary End Points
During the course of the trial, 83 patients in the 
subcutaneous ICD group and 68 patients in the 
transvenous ICD group died (hazard ratio, 1.23; 
95% CI, 0.89 to 1.70) (Table 3 and Fig. S5). 
Causes of death are presented in Table S12. In 
each group, 18 patients died suddenly.
Appropriate ICD shocks were more frequent 
in patients in the subcutaneous ICD group than 
in those in the transvenous ICD group (19.2% vs. 
11.5%; hazard ratio, 1.52; 95% CI, 1.08 to 2.12) 
(Table 3 and Fig. S6) and included subcutaneous 
ICD shocks due to oversensing of ventricular 
tachycardia below the programmed therapy zone 
in 11 patients. Appropriate antitachycardia pac-
ing was delivered in 12.9% of the patients in the 
transvenous ICD group and successfully termi-
nated 55% of all treated episodes of ventricular 
tachycardia. A total of 5 patients in the subcuta-
neous ICD group underwent implantation of a 
transvenous device for pacing for the treatment 
of bradycardia. There were no between-group 
differences in the cumulative incidence of major 
adverse cardiac events, hospitalization for heart 
failure, or total crossovers (Table 3), although 
there were numerically more crossovers during 
follow-up (shortly after the implantation attempt 
or later in follow-up) from the subcutaneous ICD 
to the transvenous ICD (14 patients) than vice 
versa (5 patients).
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Discussion
In this trial, we found that the subcutaneous 
ICD was noninferior to the transvenous ICD 
with respect to device-related complications or 
inappropriate shocks in patients with an indica-
tion for defibrillator therapy but with no indica-
tion for pacing. The results were consistent in 
several sensitivity analyses and subgroup analy-
ses. We observed equal numbers of sudden car-
diac deaths in the two groups, but there were 
numerically more deaths from other causes in 
the subcutaneous ICD group than in the trans-
venous ICD group.
With respect to the two components of the 
primary outcome, there was a higher cumula-
tive incidence of device-related complications in 
the transvenous ICD group and a higher cumula-
tive incidence of inappropriate shocks in the sub-
cutaneous ICD group, although the trial was not 
powered for these comparisons. Perspectives may 
vary among physicians and patients about which 
component poses a heavier burden: whereas com-
plications are associated primarily with physical 
distress, ICD shocks can have profound psycho-
logical implications.13
The overall incidence of complications in this 
trial was as anticipated and was similar to that 
in previous studies.4,14,15 Fewer lead-related com-
plications (including infection, perforation, lead 
dislodgement, and lead dysfunction) and subse-
quent surgical reinterventions occurred in the 
subcutaneous ICD group than in the transve-
nous ICD group, but this effect was counterbal-
anced by more frequent pocket hematomas with 
the subcutaneous ICD. The use of general anes-
thesia and defibrillation testing was much great-
er with the subcutaneous ICD than with the 
Figure 2. Time-to-First-Event Curves for the Primary 
End Point and Its Components.
Shown is the cumulative incidence of the first occur-
rence of the composite primary end point (Panel A) 
and its components, the first device-related compli-
cation (Panel B) and the first inappropriate shock 
(Panel C). Hazard ratios were derived from Cox regres-
sions and indicate the relative risk (subcutaneous ICD 
vs. transvenous ICD) of the end point. The 95% confi-
dence intervals were not adjusted for multiple compar-
isons and therefore should not be used to infer defini-
tive treatment effects. Insets show the same data on 
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transvenous ICD. Longer-term follow-up of this 
cohort will be important because the incidence 
of lead-related complications increases over time 
with the transvenous ICD16 and because battery 
longevity is a limiting factor for the subcutane-
ous ICD.17








Primary composite end point — no. (%) 68 (15.1) 68 (15.7) 0.99 (0.71–1.39)†
Components of primary end point
Device-related complication — no. (%) 31 (5.9) 44 (9.8) 0.69 (0.44–1.09)
Infection — no.‡ 4 8
Bleeding — no. 8 2
Thrombotic event — no. 1 2
Pneumothorax — no.§ 0 4
Lead perforation — no.§ 0 4
Tamponade — no. 0 2
Lead repositioning — no.§ 2 7
Other lead or device complication — no. 19 20
Lead replacement§¶ 3 9
Device malfunction 4 6
Sensing issues 4 0
Pacing indication‖ 5 1
Implantation failure 0 3
Defibrillation test failure** 3 0
Pain or discomfort 2 3
Inappropriate shock — no. (%)†† 41 (9.7) 29 (7.3) 1.43 (0.89–2.30)
Atrial fibrillation or supraventricular tachycardia 
— no.
11 27
Cardiac oversensing — no.‡‡ 24 2
Noncardiac oversensing — no.§§ 8 0
*  Percentages are 4-year cumulative incidences based on Kaplan–Meier estimates in time-to-first-event analyses. Multiple 
end points could occur in one patient; only the first end point was included in the estimation of the cumulative inci-
dence. For all end points, the sample included all the patients in the trial group. The widths of the 95% confidence 
intervals have not been adjusted for multiplicity and therefore should not be used to infer definitive treatment effects.
†  P = 0.01 for noninferiority; P = 0.95 for superiority.
‡  This category included lead-related infections in one patient in the subcutaneous ICD group and in five in the transve-
nous ICD group.
§  This end point was included in the composite end point “lead-related complications” (Fig. S2).
¶  In the subcutaneous ICD group, lead replacements were due to dislocation in two patients and to myopotential over-
sensing in one. In the transvenous ICD group, lead replacements were due to lead dysfunction in six patients and to 
lead dislodgement in three.
‖  In the subcutaneous ICD group, three patients received a pacemaker, one received a cardiac-resynchronization therapy 
device with a defibrillator (CRT-D), and one crossed over to transvenous ICD therapy — all for pacing for the treat-
ment of bradycardia. In the patient in the transvenous ICD group who had previously crossed over to subcutaneous 
ICD therapy, sick-sinus syndrome later developed, for which a pacemaker was implanted.
**  This category included defibrillator test failures that led to surgical reintervention.
††  The subcutaneous ICD sensing filter (SMART Pass) was not activated or was unavailable in 78% of the first inappro-
priate shocks in the subcutaneous ICD group.
‡‡  This category included T-wave and P-wave oversensing and includes shock on atrial fibrillation or supraventricular 
tachycardia below the detection limit in five patients in the subcutaneous ICD group.
§§  This category included myopotential and noise oversensing.
The New England Journal of Medicine 
Downloaded from nejm.org by ${individualUser.givenNames} ${individualUser.surname} on August 14, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 383;6 nejm.org August 6, 2020534
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Patients with a subcutaneous ICD had a 
higher risk of inappropriate shock than antici-
pated; the shocks were most frequently precipi-
tated by oversensing of cardiac signals (predomi-
nantly T waves) and noncardiac signals. Although 
shocks on supraventricular arrhythmias can 
generally be managed with device reprogram-
ming or medication, shocks caused by cardiac 
or noncardiac oversensing are less modifiable. 
However, a sensing filter that attenuates over-
sensing, which resulted in a 50% reduction of 
first inappropriate shocks in an earlier study, 
was introduced in a later stage of the trial.18 This 
filter was unavailable or not activated in the 
majority (78%) of patients with a subcutaneous 
ICD during their first inappropriate shock. There-
fore, this trial could not assess the potential 
benefit of the sensing filter. Such changes to 
device technology may improve the future per-
formance of the subcutaneous ICD.
We observed a higher cumulative incidence of 
appropriate shocks with the subcutaneous ICD 
than with the transvenous ICD, which was, for 
the most part, explained by the inability of the 
subcutaneous ICD to deliver antitachycardia pac-
ing. Antitachycardia pacing terminated ventricu-
lar tachycardia in more than half the pacing at-
tempts with the transvenous ICD. In addition, 
the sensing of the subcutaneous ICD, which is 
based on morphologic features, can result in 
double-counting of slow ventricular tachycardia 
occurring at a rate below the programmed ther-
apy zone, thus causing the sensed rate (if both 
QRS complexes and T waves are counted) to 
exceed the therapy threshold. According to the 
end-point definition, which was based on earlier 








Death from any cause — no. (%) 83 (16.4) 68 (13.1) 1.23 (0.89–1.70)
Sudden cardiac death — no.† 18 18
Death from other cardiovascular causes — no. 34 28
Death from noncardiovascular causes — no. 31 22
Appropriate shock therapy — no. (%) 83 (19.2) 57 (11.5) 1.52 (1.08–2.12)
Ventricular fibrillation — no. 32 22
Ventricular tachycardia within therapy zone — no. 57 41
Ventricular tachycardia below therapy zone — no.‡ 11 0
Antitachycardia pacing — no. (%)§
Appropriate 6 (0.6) 54 (12.9)
Inappropriate 1 (0.3) 30 (7.2)
Major adverse cardiac event — no. (%) 64 (13.3) 80 (16.4) 0.80 (0.57–1.11)
Hospitalization for heart failure — no. (%) 79 (17.4) 74 (16.1) 1.08 (0.79–1.49)
Crossover to other study device — no. (%) 18 (4.3) 11 (2.7) 1.64 (0.77–3.47)
Before initial implantation — no. 4 6
During implantation or follow-up — no. 14 5
Upgrade to CRT-D — no. (%) 16 (3.5) 21 (4.2)
*  Percentages are 4-year cumulative incidences based on Kaplan–Meier estimates in time-to-first-event analyses. For all 
end points, the sample included all the patients in the trial group. The widths of the 95% confidence intervals were not 
adjusted for multiplicity and therefore should not be used to infer definitive treatment effects.
†  This category included death from unexplained causes.
‡  These shocks were delivered on ventricular tachycardia below the programmed therapy limit with oversensing of car-
diac signals. The sensing filter (SMART Pass) was not activated or was unavailable in 91% of the first occurrences of 
such events.
§  Patients who received antitachycardia pacing in the subcutaneous ICD group had previously crossed over to transve-
nous ICD therapy or had received a CRT-D.
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ICD trials, these shocks were classified as ap-
propriate but — although occasionally clinical-
ly desirable — could be considered to be un-
necessary.19,20
This trial has several limitations. First, the 
members of the clinical-events committee were 
aware of the trial-group assignments. Second, 
device technology evolved throughout the trial, 
and practitioners who performed the implanta-
tions had less experience with the subcutaneous 
ICD than with the transvenous ICD, which could 
have affected clinical outcomes. Third, screen-
ing data were incomplete, and thus selection 
bias could not be ruled out. Fourth, 27 patients 
were excluded before device implantation, 38 
patients were lost to follow-up, and 126 patients 
died before having a primary end-point event. 
However, sensitivity analyses yielded consistent 
results. Fifth, it is debatable whether the magni-
tude of the possible between-group difference as 
reflected by the noninferiority margin is clini-
cally acceptable. Finally, the median follow-up of 
48 months was too limited to provide informa-
tion on chronic complications. Long-term follow-
up is therefore warranted and is ongoing.
The results of our trial showed that among 
patients with an indication for ICD therapy but 
not for pacing therapy, the subcutaneous ICD 
was noninferior to the transvenous ICD with 
respect to the cumulative incidence of the pri-
mary end point of device-related complications 
or inappropriate shocks.
A data sharing statement provided by the authors is available 
with the full text of this article at NEJM.org.
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